1:00 pm2017
Sponsored by

Nucleic Acid Tests for Accelerated Anti-Malarial Drug and Vaccine Discovery


Sean C. Murphy, MD, PhD, Assistant Professor, Department of Laboratory Medicine, University of Washington

This webinar will discuss how new quantitative polymerase chain reaction (qPCR) and reverse transcription qPCR (RT-qPCR) tests can accelerate the discovery and development of much-needed anti-malarial drugs and vaccines.  

Novel anti-malaria drugs and vaccines are currently evaluated using the Controlled Human Malaria Infection (CHMI) model, in which human volunteers receive a candidate drug or vaccine and are "challenged" with live Plasmodium falciparum sporozoites. Participants are then followed closely during the ensuing month, and if investigators detect the presence of malaria parasites in peripheral blood, it can indicate that the drug or vaccine was ineffective.

Historically, the gold standard test for erythrocyte stage Plasmodium infection has been microscopic examination of thick blood smears (TBS), which is analytically sensitive to 5-10 parasites per microliter of whole blood under ideal conditions. Because participants can be symptomatic prior to becoming TBS-positive, CHMI studies traditionally housed participants in a hospital ward or hotel during the potential symptomatic period. 

More recently, qPCR/RT-qPCR-based tests have improved the analytical sensitivity of infection detection by several orders of magnitude and now permit pre-symptomatic infection detection. Such tests accelerate infection detection compared to TBS and enable CHMI studies to be conducted without domiciling participants.

In this webinar, Sean Murphy of the University of Washington will discuss efforts to improve the limit of detection for Plasmodium 18S rRNA/rDNA assays to 10-20 parasites per milliliter of blood. His presentation will describe how such tests have reduced the costs, complexity, and risks of CHMI studies by accelerating infection detection and will detail external quality assurance efforts between laboratories that corroborate these diagnostic improvements. 

Sponsored by

Cheif Scientific Officer & Senior Vice President, Laboratory Corporation of America

Medical Oncologist, Assistant Professor of Medicine, UC San Diego Moores Cancer Center


Founder & Cheif Scientific Officer, Omniseq

This webinar will discuss the advantages of a multiple-biomarker-based approach for immune profiling that provides clinicians with a rational means to consider approved immunotherapies or assign patients to immunotherapy clinical trials.

Assays that measure a single type of biomarker – such as mutational burden assays – are important, but can be misleading for informing cancer immunotherapy treatment selection. Comprehensive immune profiling strategies that incorporate standard biomarkers alongside RNA-seq can be more informative, based upon the hypothesis that overexpression of an immune marker should correlate with therapeutic benefit as in the case of HER2 and Herceptin.

This comprehensive immune profiling approach could potentially impact as many as half of patients who are not PD-L1 IHC positive (tumor proportion score of 50%) or mutational burden high.

This webinar will include insights from the OmniSeq reference population, a review of comprehensive immune profiles from clinical cases at UC San Diego, and implications for immunotherapy from LabCorp.

Sponsored by
1:00 pm2017
Sponsored by

Validation of a UMI-Powered NGS Panel for Improved Variant Calling


Director, Labsolutions, LLC

Global Product Manager, Qiagen

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Targeted NGS panels have been instrumental in advancing the field of cancer genomics by enabling the analysis of hundreds of mutations across many genes in an individual assay.

The biggest challenges, however, to realizing the full benefits of targeted NGS panels are 1) PCR duplicates and errors introduced during the workflow, which result in reduced confidence in calling variants such as single nucleotide variants and indels; 2) low levels of enrichment and sequencing uniformity, which affect the ability to call low-frequency variants; and 3) long turnaround times and high DNA input requirements, which limit the practicality of NGS panels.

These challenges can be overcome by building a robust workflow with short turnaround times that incorporates unique molecular indices (UMIs) to correct for PCR errors and single primer extension (SPE) to enhance uniformity and reduce the DNA input requirements.

During this webinar, Dr. Bernadette Wildemore of Labsolutions will discuss the validation of a UMI-powered DNA panel and associated bioinformatics pipelines in high-throughput routine use. Dr. Raed Samara of Qiagen will then discuss the benefits of incorporating UMIs and SPE to overcome the current challenges of using targeted NGS panels.

Sponsored by

Assistant Professor, Washington University 

Director, Technical Support, NuGEN

This webinar will discuss the role of a newly discovered, brain-enriched form of non-CpG DNA methylation in neural development and disease.

Neurons in the brain must express diverse complements of genes in order to form synaptic connections and execute physiological responses to stimulation. But how is this complex neuronal transcriptome regulated? Do unique mechanisms exist in neurons to control this process?

In this webinar, Harrison Gabel of Washington University will describe a study that used chromatin immunoprecipitation-sequencing, RNA-sequencing, and whole-genome bisulfite-sequencing to demonstrate that uniquely high levels of non-CpG methylation in the brain play a critical role in regulating neuron-specific transcriptional programs.

Dr. Gabel and colleagues have further uncovered evidence that this non-CpG DNA methylation is an important binding site for MeCP2, the protein disrupted in the neurological disorder Rett syndrome.

Dr. Gabel will describe these and other studies that have used genomic methods to define how methylated CA (mCA) accumulates in neurons, determine the molecular mechanism of transcriptional regulation mediated by mCA and MeCP2, and understand how disruption of this gene-regulatory pathway contributes to neurodevelopmental disease.

Sponsored by

Senior Director, Division of Advanced Research Technologies, New York University School of Medicine

Assistant Director, Hoglund Brain Imaging Ctr.,University of Kansas Medical Center

In these times of economic constraint and increasing research costs, shared resource cores have become a cost-effective and essential platform for researchers who seek to investigate complex translational research questions. Cores produce significant value that cannot be captured using traditional financial metrics. Benchmarking studies conducted by the Association of Biomolecular Resource Facilities and other organizations indicate that most research cores do not fully recover operating expenses. As such, these “operational losses” represent institutional investment, which, if well planned and managed, produce future returns for the institution’s research community that extend far beyond subsidized pricing.

Current literature indicates that there is no single measure that can provide an accurate representation of the full picture of the return on research investments.

This presentation attempts to provide instruction and examples using the Balanced Score Card (BSC), (Kaplan and Norton), as a tool for assessing the return on investment for research core facilities.

The BSC supplements traditional financial measures with criteria to measure performance in three additional areas — customers, internal business processes, and learning and growth. The presenters will also discuss and share their experiences on how they have utilized these ROI approaches to streamline their core operations and make sound investment decisions and strategies to further the mission of their institutions and to meet the expectations of their various investors and key stakeholders.

Sponsored by
12:00 pm2017
Sponsored by
Agilent Technologies

Combined Mutation Detection and Copy Number Profiling by Error-Corrected ctDNA Sequencing


Clinician Scientist & Medical Oncologist,
Institute of Cancer Research, London and the Royal Marsden Hospital

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.

Mutations and DNA copy number aberrations (CNAs) are important predictive biomarkers in cancer medicine, but spatial intratumor heterogeneity can hinder accurate cancer profiling from biopsies and cancer evolution alters genomic profiles over time.

Circulating tumor DNA (ctDNA) sequencing may overcome these hurdles by enabling multi-timepoint testing and the detection of subclones that are disseminated in space.

In this webinar, Dr. Marco Gerlinger of the Institute of Cancer Research, London, will discuss an approach that combines solution hybrid capture for target enrichment and molecular barcodes for sequencing error correction. This customizable ultra-sensitive ctDNA sequencing technology can be applied to 25 ng of ctDNA, a quantity that can usually be obtained from 10-20 ml of blood. Deep sequencing of the target region with over 20,000x depth enables mutation detection in driver gene panels with a sensitivity of up to 0.1%. The analysis of off-target reads allows simultaneous genome-wide CNA profiling.

Sample preparation, sequencing, and data analysis workflows as well as a concordance analysis of ctDNA and tumor sequencing in colorectal cancers will be presented in the webinar.

Sponsored by
Recent GenomeWebinars

Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research Division; Assistant Professor, University of Washington, Division of Oncology

This webinar discusses the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.

Sarcomas are a group of more than 70 cancers of mesenchymal origin that together comprise approximately 1 percent of all cancers. On initial presentation, these tumors are often localized and curable. Surgery is the mainstay of therapy, but radiation and sometimes chemotherapy can also play an important role.

Unfortunately, even with state-of-the-art care, more than 50 percent of patients with large, high-grade tumors will develop advanced disease. Immunotherapy has the potential to cure many of these patients, but little is known about the changing immune microenvironment during neoadjuvant treatment for soft tissue sarcoma.

During this webinar, Seth M. Pollack of Fred Hutchinson Cancer Research Center discusses a study that used multiple approaches to generate a molecular profile of these cancers. He provides details of how Cofactor Genomics' Paragon assay was used to dissect the changing tumor immune microenvironment in soft tissue sarcoma during neoadjuvant therapy and share results from the study.   

Sponsored by

Director of the Laboratory for Clinical Genomics & Advanced Technology, Dartmouth-Hitchcock Medical Center & Norris Cotton Cancer Center; Professor of Pathology & Laboratory Medicine, Audrey & Theodor Geisel School of Medicine at Dartmouth

Senior Member & Chair, Department of Anatomic Pathology, Moffitt Cancer Center;  Executive Director of Esoteric Laboratory Services, Morsani Molecular Diagnostic Laboratory & Scientific Director of the Moffitt Tissue Core

 Associate Professor of Pathology, Associate Director of the Residency Program, Medical Director of Cytogenetics Laboratory & Director Georgia Esoteric & Molecular Laboratory, Augusta University

Founder & Chief Biomedical Informatics Officer, PierianDx

This webinar discussed the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.

Our expert panel — Gregory Tsongalis from Dartmouth-Hitchcock, Anthony Magliocco from Moffitt Cancer Center, Ravindra Kolhe from Augusta University, and Rakesh Nagarajan from PierianDx — specifically discuss their experiences with Illumina’s TruSight Tumor 170 targeted cancer assay.

The TST170 next-generation sequencing-based panel targets single nucleotide variants, indels, gene amplifications, gene fusions, splice variants, mRNA expression, and mRNA isoform detection found in 170 cancer-related genes and also calculates metrics such as tumor mutation burden and determines evidence for microsatellite instability.

Our panelists discuss the design of the assay, data analytics, and reasons behind their selection of the TST170 assay, and share details of how it is being utilized within their organizations. 

Sponsored by

Director, Proteomics Shared Resource, Herbert Irving Comprehensive Cancer Center; Assistant professor of Dept. Pharmacology, Columbia University Medical Center

Director, Genome Center Proteomics Facility, 
University of California

Director, Proteomics & Mass Spectrometry Facility,
Research Professor, Biochemistry & Molecular Pharmacology
University of Massachusetts Medical School

Professor, Division of Molecular Biology & Human Genetics
Stellenbosch University Faculty of Medicine & Health Sciences

This webinar answers researchers’ most pressing questions about how to gain outstanding research results from proteomic studies

Researchers and clinicians are increasingly adopting proteomics as a go-to method for gaining biological insights and direction. Proteomic core labs are shared resources with the expertise and instrumentation to carry out these specialized studies. Collaboration between researcher and proteomic core combines the expertise and leverages the strengths of both parties. This webinar provides building blocks on which to jumpstart or strengthen this key relationship.

From study design and sample preparation through data analysis, result interpretation, and overall reproducibility, our panelists will answer your essential questions about setting up and carrying out high-quality proteomic studies. This practical insider info will help researchers and cores to work together and effectively move research forward.


About the GenomeWeb ABRF Webinar Series
GenomeWeb and the Association of Biomolecular Resource Facilities are partnering for the second year to produce a series of online seminars highlighting methods, techniques, and instrumentation that support life science research. Special thanks to the series sponsor, PerkinElmer!

For information on other webinars in the series, please click here.


Sponsored by
1:00 pm2017
Sponsored by
Fabric Genomics

Clinical Utility of Comprehensive and Fast Genomic Interpretation


Sr. Director of Clinical Operations, 
Rady Children’s Institute for Genomic Medicine

Scientist, Fabric Genomics

This webinar discusses the critical role of genomic interpretation software for clinical labs looking to establish comprehensive NGS testing programs. Accurate and fast software for variant calling, alignment, interpretation, and clinical reporting is an essential component of genomic medicine, with the potential to significantly impact patient outcomes and improve healthcare economics.

In this webinar, Shareef Nahas of Rady Children’s Institute for Genomic Medicine (RCIGM) presents various case studies that demonstrate how Fabric Genomics’ Opal Clinical software helps achieve accurate and rapid whole-genome interpretation of disease-causing variants in critically ill children.

RCIGM’s goal is a 24-hour turnaround time from blood sample to clinical report. Dr. Nahas discusses key interpretation and reporting capabilities needed to launch and scale clinical NGS testing, including the need for advanced computational algorithms to maximize diagnostic yield.

Our second speaker, Vanisha Mistry of Fabric Genomics, addresses best practices for adoption, deployment, and scaling of genomic data analysis platforms in the clinical lab, including automation and streamlining NGS workflows. She will review sample workflows for panels, exomes, and genomes, and will demonstrate their value to clinical labs.

Sponsored by

Associate Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center

Chief Technology Officer, Philips Genomics

This webinar presents an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Michael Berger, Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center, discusses the implementation of MSK-IMPACT, an NGS panel that analyzes both tumor and matched normal tissue to detect protein-coding mutations, copy number alterations, and certain promoter mutations and structural rearrangements in cancer-associated genes.

The panel, which currently covers 468 genes, has allowed a large number of patients to enroll in clinical trials of targeted treatments, according to a study published by Berger and colleagues earlier this year based on the results from sequencing around 10,000 patients. The MSKCC team found that around a third of these patients harbored actionable mutations and 11 percent of patients participated in a genomically matched clinical trial based on their results.

Since then, the MSKCC team has profiled a total of 20,000 patients with the panel. Dr. Berger discusses lessons learned from this implementation process, including:

  • Considerations in assay design
  • Challenges in large-scale implementation
  • Integration with informatics systems
  • Assessment of clinical utility
  • Opportunities for clinical, translational, and basic research

Dr. Nevenka Dimitrova discusses how the Philips IntelliSpace Genomics platform addresses the challenges of implementing molecular profiling panels at healthcare systems with integrated clinical-genomic data, up-to-date variant interpretation and seamless workflow for precision oncology.

Sponsored by

Research Scientist, Technology Innovation Lab, New York Genome Center

This webinar describes a protocol and proof-of-principle experiments for Cellular Indexing of Transcriptome and Epitopes by Sequencing (CITE-seq).

CITE-seq combines unbiased genome-wide expression profiling with the measurement of a potentially limitless number of specific protein markers in thousands of single cells.

Marlon Stoeckius, Research Scientist in the Technology Innovation Lab of the New York Genome Center, presents the approach, which first requires conjugating monoclonal antibodies to oligonucleotides containing unique antibody identifier sequences. Next, a cell suspension is labeled with the DNA-barcoded antibodies and single cells are subsequently encapsulated into nanoliter-sized aqueous droplets in a microfluidic apparatus. In each droplet, cells are lysed, antibody and cDNA molecules are indexed with the same unique barcode, and the resulting molecules are converted into libraries. The protein-encoding and RNA-derived libraries can be amplified independently and mixed in appropriate proportions for sequencing in the same lane.

Dr. Stoeckius discusses proof-of-concept experiments, highlight the method’s compatibility with existing single-cell sequencing approaches, and describes how it can readily scale as the throughput of these methods increases.

Sponsored by

Medical Director, Molecular Oncology Diagnostics Lab
The Ottawa Hospital

This webinar demonstrates a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

The need to process small quantities of solid tumor specimens is increasing as early detection strategies become more effective and less invasive biopsy strategies are adopted. Moreover, the rapidly changing landscape of molecular testing points towards a need for minimizing sample input and preservation of sample for future testing. Processing small areas of dissected tumor can be challenging as traditional manual macrodissection and purification methods include multiple steps during which material can be lost.

In this webinar, Bryan Lo, Medical Director of the Molecular Oncology Diagnostics Lab at the Ottawa Hospital, presents a new approach that combines automated tissue dissection with NGS library prepared directly from fragments of dissected tissue.

Dr. Lo discusses a study that demonstrated that gene expression profiling of pancreatic cancer and precursor lesions extracted by automated tissue dissection system yielded highly correlated data across tissue samples. Furthermore, mutation screening of dissected tissue fragments from melanoma and colorectal cancer showed high correlation between libraries prepared from an extraction-free method vs extracted DNA.

Taken together, these findings demonstrate that an automated tissue dissection approach joined with extraction-free library preparation can help efficiently process extremely small samples that are otherwise too challenging for standard NGS analysis.

Viewers of this webinar will learn the following:

  • Current challenges with isolating precise tumor areas of interest from FFPE tissue samples
  • How a high-performance, automated tissue dissection system can extract challenging tumor tissue fragments precisely and consistently
  • How to subsequently prepare NGS libraries using extraction-free methods to further reduce the risk of sample loss
Sponsored by
1:00 pm2017
Sponsored by
Ion Torrent

Latest Advances in Tumor Genomic Profiling for Challenging Samples


Clinical Assistant Professor, Pathology, University Hospitals Cleveland Medical Center  

Associate Director, Oncology Product Management, Thermo Fisher Scientific 

This webinar discusses how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Recent studies estimate that almost 73 percent of cancer treatments in the pipeline may need a genomic biomarker in the next few years. As the list of genomic biomarkers relevant to clinical oncology keeps growing, the ability to detect mutations across hundreds of targets in a rapid, cost-efficient fashion helps pathology research laboratories conserve samples by reducing the need for sequential, single-analyte assays. NGS panels have revolutionized the field of cancer genomics by enabling pathologists and clinical researchers to analyze mutations across multiple genes, in a single assay.

For clinical research or pathology laboratories that are considering adopting NGS in house, it’s important that the chosen solutions are compatible with challenging sample types (such as fine needle aspirates and formalin-fixed, paraffin-embedded samples), have an automated wet-lab workflow, and offer plug-and-play bioinformatics capabilities.

During this webinar, Dr. Navid Sadri of the University Hospitals Cleveland Medical Center provides an overview of why his pathology lab adopted NGS and how it is being implemented for clinical research. He provides some examples of how NGS helped identify different mutation types and provides relevant results with limited sample input and a rapid turnaround time.

Thereafter, Dr. Jody McIntyre of Thermo Fisher Scientific shows how Oncomine KnowledgeBase Reporter can help pathologists and clinical researchers link cancer variants to labels, guidelines and clinical trials, and generate an easy-to-interpret report in a few simple steps.

Sponsored by

Associate Professor, Developmental Neuroscience, Munroe Meyer Institute for Genetics and Rehabilitation; Director of UNMC Mouse Genome Engineering Core Facility, University of Nebraska Medical Center

 Assistant Member Director, Center for Advance Genome Engineering, St. Jude Children’s Research Hospital

This webinar covers recent advances in the use of CRISPR for generating animal models and cell lines.

Our first speaker, CB Gurumurthy of the University of Nebraska Medical Center, discusses the latest CRISPR strategies and tools available for animal genome editing, with a particular emphasis on strategies for increasing the homology-directed repair mechanism to enable insertion of longer sequences.

While CRISPR has shown very high promise for creating complete knockout (deletion) and subtle genetic changes (e.g., point mutation knock-ins), the generation of complex models, such as long cassette knock-ins and conditional knockout animal models, has remained a major challenge. Dr. Gurumurthy discusses advances in this area and will present examples of designing knock-in animal models.

Our second speaker, Shondra Miller the Director of the Center for Advanced Genome Engineering at St. Jude Children’s Research Hospital, shares lessons learned from more than 2,000 genome editing projects.

Although the CRISPR/Cas9 genome editing technique is conceptually simple and relatively efficient, creating and identifying correctly targeted clones can be quite laborious. The St. Jude team uses targeted deep sequencing as a tool to help increase the rates of genome editing through more rational design of CRISPR reagents.

Dr. Miller discusses how her team has used this approach to successfully validate more than 2,000 custom guide RNAs, create more than 400 custom modified cell lines, and create more than 150 custom-modified mouse models.

Sponsored by
1:00 pm2017
Sponsored by

Improved Library Prep Workflows for Small RNA NGS in Serum and Plasma


Queens University Belfast


This webinar addresses improvements in the library prep workflow for small RNA sequencing in serum and plasma.

Sequencing of small RNAs from extracellular fluids, including serum and plasma, is a fast-growing area of biomarker research. Analysis of plasma and serum by small RNA sequencing involves isolating RNA, performing library preparation, sequencing, and downstream data analysis.

Our speaker, David Simpson of Queens University Belfast, describes the factors to be considered at each of these steps and compaers workflows from Qiagen and Bioo Scientific/PerkinElmer for small RNA sequencing from serum and plasma samples. 

The workflow from Bioo Scientific involves magnetic bead-based RNA purification followed by library preparation using adapters with randomized ends to reduce ligation bias, while the Qiagen workflow involves column-based purification of RNA followed by library preparation utilizing unique molecular identifiers for PCR bias correction. Dr. Simpson discusses metrics such as mapping rate, adapter-dimer contamination, and diversity of miRNAs detected.

Dr. Simpson also discusses the effectiveness of the alternative chemistries and randomized adapters employed by Bioo Scientific to reduce ligation bias. For example, the correction of PCR bias by use of unique molecular identifiers in the Qiagen workflow had little effect upon relative miRNA quantification, suggesting that reduction of ligation bias is a more effective strategy to reduce bias in small RNA library preparation. 

Sponsored by
1:00 pm2017
Sponsored by

Characterization of Gene Fusions in Distinct Subtypes of Melanoma


Research Instructor, Cutaneous Oncology Program,
Division of Medical Oncology, Department of Medicine,
University of Colorado Anschutz Medical Campus

Director, Technical Support, NuGen

This webinar describes the characterization of gene fusions across distinct subtypes of melanoma.

The majority of common sun exposure-related melanomas have high mutational burden and activating mutations in the BRAF kinase gene. In contrast, less common subtypes of melanoma not related to sun exposure (acral lentiginous and mucosal melanomas) have low mutation burden, generally lack BRAF mutations, and have increased frequency of genomic structural variants. Activating gene fusions in BRAF have been reported in melanomas lacking mutations in BRAF and other common melanoma driver genes, but gene fusions and their therapeutic potential have not been well studied across different subtypes of melanoma.

To characterize gene fusions, Kasey Couts and colleagues at the University of Colorado Anschutz Medical Campus performed targeted RNA sequencing of 65 melanoma patient-derived xenograft (PDX) models representing different melanoma subtypes (sun-exposed and non-sun-exposed) and genotypes (with or without common driver mutations). They identified several kinase gene fusions in melanomas lacking other driver mutations and tested the therapeutic potential in pre-clinical models using specific small molecule inhibitors.

During this webinar, Dr. Couts describes the gene fusion targeted RNA sequencing screen and discuss the results, which include identification of an ALK fusion (EML4-ALK) occurring in a malignant melanoma. She also discusses the successful response to targeted inhibitors in melanomas with various kinase fusions. This webinar highlights the clinically significant finding of targetable gene fusions in both sun-exposed and non-sun-exposed subtypes of melanoma.

Sponsored by
2:00 pm2017
Sponsored by
Philips Genomics

Validation, Then Discovery: Establishing Truth from cfDNA Genotyping of Lung Cancer


Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School

Chief Technology Officer, Philips Genomics 

This webinar provides an overview of how liquid biopsies can be integrated into lung cancer care.

Genotyping of plasma cell-free DNA is rapidly changing the management approach for genotype-defined lung cancers. Widely available assays now have the ability to noninvasively identify driver mutations in cfDNA, monitor response to therapy, and characterize emerging resistance. However, such liquid biopsies also have clear limitations and existing assays are unlikely to replace tumor biopsies completely.

In this webinar, Geoffrey Oxnard of Dana-Farber Cancer Institute discusses an optimal approach for integrating liquid biopsies into lung cancer care, while also providing his outlook on how liquid biopsies may become a routine part of lung cancer treatment in the years ahead. 

Dr. Dimitrova discusses how the Philips IntelliSpace Genomics platform brings data from liquid biopsies (and other NGS tests) alongside disease histology and patient phenotype for a complete clinical picture for clinical decision making.

Sponsored by

Associate Professor, Weill Cornell Medical College 

This online seminar provides an overview of current standardization efforts in genomics, epigenomics, and metagenomics, with a focus on practical implementation considerations for researchers and labs.

Challenges and biases in preparing, characterizing, and sequencing DNA and RNA can have significant impacts on research in genomics across all kingdoms of life, including experiments in single cells, RNA profiling, and metagenomics. Technical artifacts and contaminations can arise at each point of sample manipulation, extraction, sequencing, and analysis. Thus, the measurement and benchmarking of these potential sources of error are of paramount importance as next-generation sequencing (NGS) projects become more global and ubiquitous.  

Fortunately, a variety of methods, standards, and technologies have recently emerged that improve measurements in genomics and sequencing, from the initial input material to the computational pipelines that process and annotate the data. 

This webinar reviews work to develop standards and their applications in genomics, including the ABRF-NGS Phase II NGS Study on DNA Sequencing; the FDA’s Sequencing Quality Control Consortium (SEQC2); metagenomics standards efforts (ABRF, ATCC, Zymo, Metaquins), and the Epigenomics QC group of the SEQC2. The webinar will also review he computational methods for detection, validation, and implementation of these genomic measures.


About the GenomeWeb/ABRF 2017 Webinar Series: GenomeWeb has partnered with the Association of Biomolecular Resource Facilities  for the second year to produce a series of online seminars highlighting methods, techniques, and instrumentation that support life science research. More information about ABRF and its activities is available here. Please check GenomeWeb's webinar schedule for future webinars in this series. The series is sponsored by PerkinElmer.

Sponsored by